)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Sage Therapeutics (SAGE) investor relations material
Sage Therapeutics Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary30 Jul, 2025
Executive summary
Entered into a definitive merger agreement with Supernus Pharmaceuticals, offering $8.50 per share plus up to $3.50 per share in CVRs, with total consideration up to $795M; transaction expected to close after July 30, 2025, pending customary conditions.
ZURZUVAE, the first oral treatment for postpartum depression, continues U.S. commercial launch with over 4,000 prescriptions shipped in Q2 2025, a 36% sequential increase.
Cash, cash equivalents, and marketable securities totaled $366M as of June 30, 2025.
Discontinued ZULRESSO as of December 2024 and withdrew its NDA in April 2025; pipeline reprioritized following negative trial results for dalzanemdor and SAGE-324.
Over 13,500 ZURZUVAE prescriptions since launch; 80% of Q2 2025 prescriptions from OBGYNs; 80% first-time PPD treatment.
Financial highlights
Total revenue for Q2 2025 was $31.7M, up from $8.7M in Q2 2024; six-month revenue was $45.7M, up from $16.6M year-over-year.
Collaboration revenue from ZURZUVAE was $23.2M in Q2 2025, up from $7.4M in Q2 2024.
Net loss for Q2 2025 was $49.7M, improved from $102.9M in Q2 2024; net loss per share was $(0.79), improved from $(1.70).
R&D expenses decreased to $23.9M in Q2 2025 from $62.6M in Q2 2024; SG&A expenses increased to $62.0M from $56.0M year-over-year.
Other collaboration revenue reached $8.5M in Q2 2025, up from $0.6M in Q2 2024.
Outlook and guidance
Current cash and expected revenues, excluding milestones, projected to fund operations through mid-2027.
Anticipates significant topline revenue growth for ZURZUVAE in 2025, supported by expanded sales force and marketing.
Operating expenses expected to decrease in 2025 due to restructuring and pipeline prioritization, but significant commercialization and development costs will continue.
Focus remains on ZURZUVAE commercialization, SAGE-319 development, and evaluating SAGE-324 for new indications.
Expects Phase 1 MAD study data for SAGE-319 by late 2025 and an update on SAGE-324 in mid-2025.
Explain the rationale for SAGE-324 evaluation.
Assess Supernus's potential benefits from the acquisition.
How will ZURZUVAE's commercialization investment impact revenue?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Sage Therapeutics earnings date
Q3 202529 Oct, 2025
Next Sage Therapeutics earnings date
Q3 202529 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Sage Therapeutics Inc is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system (CNS) disorders. Its research targets psychiatric, neurological, and neurodevelopmental conditions. The company operates across the drug discovery, clinical development, and commercialization stages, aiming to address unmet medical needs in brain health. Sage Therapeutics Inc is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage